Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

NCT05039801 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05039801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
September 30, 2021
Completion date
June 30, 2028
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial carcinoma, advanced head and neck squamous cell carcinoma, advanced malignant solid neoplasm, advanced melanoma, advanced ovarian clear cell adenocarcinoma, chondrosarcoma, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, recurrent ovarian high grade serous adenocarcinoma, refractory endometrial carcinoma, refractory head and neck squamous cell carcinoma, refractory melanoma, refractory ovarian clear cell adenocarcinoma, refractory ovarian high grade serous adenocarcinoma, stage iii ovarian cancer ajcc v8, stage iii uterine corpus cancer ajcc v8, stage iiia ovarian cancer ajcc v8, stage iiia uterine corpus cancer ajcc v8, stage iiia1 ovarian cancer ajcc v8, stage iiia2 ovarian cancer ajcc v8, stage iiib ovarian cancer ajcc v8, stage iiib uterine corpus cancer ajcc v8, stage iiic ovarian cancer ajcc v8, stage iiic uterine corpus cancer ajcc v8, stage iiic1 uterine corpus cancer ajcc v8, stage iiic2 uterine corpus cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv uterine corpus cancer ajcc v8, stage iva ovarian cancer ajcc v8, stage iva uterine corpus cancer ajcc v8, stage ivb ovarian cancer ajcc v8, stage ivb uterine corpus cancer ajcc v8